Gyre Therapeutics, Inc.
NASDAQ:GYRE · NASDAQ Capital Market
+$0.00 today
Vol 0.06M · Avg 0.09M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
4.7%
avg 0.1%
ROIC
5.3%
avg -51.0%
ROA
3.0%
avg -43.7%
Analysis
ROIC is currently the strongest return metric at 5.3% versus its period average of -51.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ping Zhang | Interim Chief Executive Officer & Executive Chair | $578,861.00 | — | 53 | $0.00 | <0.01% |
Weiguo Ye | Chief Operating Officer | $563,414.00 | — | 48 | $700,000.00 | 0.72% |
Han Ying | Senior Vice President of Science | $353,315.00 | — | 60 | $120,000.00 | 0.12% |
Ruoyu Chen | Chief Information Officer | $285,583.00 | — | 55 | $50,000.00 | 0.05% |
Ying Luo | CEO, President & Director | $85,000.00 | — | 61 | $120,000.00 | 0.12% |
Thomas W. Eastling | Chief Financial Officer | $50,000.00 | — | 67 | $33,271.00 | 0.03% |
Jing Liu | Senior Vice President of Platform Chemistry | — | — | — | — | — |
Mark Marino | Senior Vice President of Clinical Development | — | — | — | — | — |
Michael Plewe | Senior Vice President - Medicinal Chemistry | — | — | — | — | — |
Jialiang Wang | Executive VP & GM | — | — | — | $0.00 | <0.01% |
Joshua Bergmann | General Counsel & Corporate Secretary | — | — | — | $50,000.00 | 0.05% |
Songjiang Ma | President & Director | — | — | 70 | $2.81M | 2.89% |
Seth Goldblum | Senior Vice President of Corporate Development | — | — | — | — | — |
Yue Xiong | Chief Scientific Officer | — | — | — | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
14
$826,364.76
Net Sentiment
$826,364.76
Net selling
Most Active
Ye Weiguo
12 transactions
1–10 of 14
Analysis
Insiders reported 0 buys worth $0.00 and 14 sells worth $826,364.76 over the last 12 months. That adds up to net selling of $826,364.76. Ye Weiguo was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -68.8% | +41.1% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -68.8% over three years. Forward estimates point to Revenue at +41.1% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.28B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.48B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.42B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.40B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.37B
MeiraGTx Holdings plc
NASDAQ:MGTX
$1.03B
Astria Therapeutics, Inc.
ATXS
$718.13M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$471.21M
Keros Therapeutics, Inc.
NASDAQ:KROS
$336.46M
Anavex Life Sciences Corp.
NASDAQ:AVXL
$244.19M
Who manages GYRE?
Gyre Therapeutics, Inc. (GYRE) lists 14 active executives. The top listed executive is Han Ying, Senior Vice President of Science.
Are GYRE insiders buying or selling?
Recent insider activity shows net buying of $13.43M.
Explore More
Continue the stock analysis
Jump to another research area for this company.